Key terms
About RCEL
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RCEL news
Mar 01
7:48am ET
TD Cowen Keeps Their Buy Rating on Avita Medical (RCEL)
Feb 29
5:00pm ET
Avita Medical submits response to FDA for Recell Go PMA
Feb 23
7:33am ET
Piper Sandler Sticks to Its Buy Rating for Avita Medical (RCEL)
Feb 23
7:29am ET
Avita Medical price target raised to $26 from $20 at BTIG
Feb 23
7:18am ET
Avita Medical price target raised to $25 from $22 at Cantor Fitzgerald
Feb 23
5:18am ET
Avita Medical Poised for Growth: Strong Q4 Performance and Promising 2024 Outlook Reinforce Buy Rating
Feb 22
10:35pm ET
Buy Rating Affirmed for Avita Medical on Strong Financials and Expansive Growth Strategy
Feb 22
4:04pm ET
Avita Medical reports Q4 EPS (28c), consensus (37c)
Feb 20
8:45am ET
Avita Medical (RCEL) Receives a Buy from Lake Street
Jan 19
7:11am ET
Avita Medical named best idea for 2024 at Cantor Fitzgerald
Jan 11
9:26am ET
Avita Medical Poised for Growth: Buy Rating and $40 Price Target Justified by Strategic Partnerships and Positive Financial Indicators
Jan 11
6:36am ET
Avita Medical: A Strong Buy on Robust Growth Prospects and Solid Financials
Jan 10
4:05pm ET
Avita Medical in distribution pact with Stedical Scientific for PermeaDerm
Jan 10
9:07am ET
Avita Medical completes enrollment of TONE study earlier than anticipated
Jan 10
9:06am ET
Avita Medical sees 2024 commercial revenue $78.5M-$84.5M, consensus $75.2M
Jan 10
9:05am ET
Avita Medical sees Q1 commercial revenue $14.8M-$15.6M, consensus $15.89M
Jan 10
9:05am ET
Avita Medical sees 2023 revenue $49.8M, consensus $50.7M
Jan 10
9:04am ET
Avita Medical sees Q4 commercial revenue $14.1M, consensus $14.6M
Jan 07
5:46am ET
Avita Medical (RCEL) Gets a Buy from BTIG
Jan 02
9:47am ET
Avita Medical (RCEL) Gets a Buy from BTIG
Dec 31
5:24am ET
BTIG Sticks to Its Buy Rating for Avita Medical (RCEL)
No recent news articles are available for RCEL
RCEL Financials
Key terms
Ad Feedback
RCEL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RCEL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range